PUBLISHER: The Business Research Company | PRODUCT CODE: 1957641
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957641
Pharmaceutical native starch is unmodified starch obtained from natural sources such as corn, potato, wheat, or tapioca and used as an excipient in drug formulations. It serves as a binder, disintegrant, or filler in tablets and capsules, helping regulate medication release, enhance stability, and maintain proper tablet formation without undergoing chemical or physical modification.
The main types of pharmaceutical native starches include potato starch, corn starch, and others. Potato starch, a fine white powder extracted from potato tubers, is valued for its smooth texture and excellent binding properties, making it suitable for tablet formulations in pharmaceuticals. It is available in various dosage forms, including oral solids, liquids, topical formulations, injectables, and controlled-release forms. Its functionalities include acting as a texturizing agent, moisture-retention agent, bulking agent, emulsifier, and film-forming agent. It is applied in roles such as binders, coating agents, disintegrants, fillers and extenders, stabilizers, and thickeners, serving end users such as pharmaceutical manufacturers, contract research organizations (CROs), contract manufacturing organizations (CMOs), R&D laboratories, academic institutions, and others.
Tariffs have impacted the pharmaceutical native starch market by increasing the cost of imported starch raw materials and processing inputs used in excipient manufacturing. These effects are most visible across excipient supply chains in Asia Pacific and Europe, where pharmaceutical production depends on consistent raw material quality. Rising tariff related expenses have increased formulation costs and placed pressure on excipient pricing. This has influenced procurement decisions for pharmaceutical manufacturers and contract formulators. However, tariffs have encouraged local agricultural sourcing, expanded regional excipient manufacturing, and strengthened long term supply chain resilience.
The pharmaceuticals native starch market research report is one of a series of new reports from The Business Research Company that provides pharmaceuticals native starch market statistics, including pharmaceuticals native starch industry global market size, regional shares, competitors with a pharmaceuticals native starch market share, detailed pharmaceuticals native starch market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceuticals native starch industry. This pharmaceuticals native starch market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pharmaceuticals native starch market size has grown strongly in recent years. It will grow from $6.11 billion in 2025 to $6.64 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to availability of natural starch sources, expansion of generic pharmaceuticals, widespread use of tablets and capsules, cost sensitivity in drug formulation, regulatory acceptance of native starch.
The pharmaceuticals native starch market size is expected to see strong growth in the next few years. It will grow to $9.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to growth in clean-label drug formulations, increasing sustainability requirements, expansion of pharmaceutical manufacturing in emerging markets, rising demand for biodegradable excipients, advancements in starch processing. Major trends in the forecast period include growing demand for natural and clean-label excipients, increasing use in solid oral dosage forms, rising adoption as binder and disintegrant, expansion of plant-based pharmaceutical ingredients, increasing focus on cost-effective excipients.
The rising prevalence of chronic diseases is expected to drive the growth of the pharmaceuticals native starch market in the coming years. Chronic diseases are long-term medical conditions that typically progress slowly and last for a year or more. This increase is largely due to the aging population, as older individuals are more prone to long-term health issues such as diabetes, cardiovascular diseases, arthritis, and cancer, which become more common with age. Pharmaceuticals native starch supports the management of chronic diseases by improving drug formulation stability, enhancing bioavailability, enabling controlled drug release, promoting patient compliance, and ultimately strengthening the effectiveness and long-term management of these conditions. For example, in April 2025, data from the Centers for Disease Control and Prevention, a US-based federal public health agency, reported that 76.4% of U.S. adults-approximately 194 million people-had one or more chronic conditions in 2023, with prevalence rates of 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Consequently, the increasing prevalence of chronic diseases is contributing to the growth of the pharmaceuticals native starch market.
The growth of generic drug manufacturing is expected to drive the expansion of the pharmaceuticals native starch market in the coming years. Generic drug manufacturing involves producing off-patent medications that are bioequivalent to branded drugs. This sector is expanding due to increasing regulatory support, which accelerates approvals and encourages more companies to produce affordable alternatives to branded medicines. The expansion of generic drug manufacturing supports pharmaceuticals native starch by creating higher demand for reliable, cost-effective excipients that improve tablet formulation, stability, and drug delivery efficiency across a wide range of high-volume generic products. For example, in November 2024, data from the Food and Drug Administration (FDA), a US-based federal agency, reported that in FY 2023, the FDA approved 782 Abbreviated New Drug Applications (ANDAs), up from 722 approvals in FY 2022. Consequently, the expansion of generic drug manufacturing is contributing to the growth of the pharmaceuticals native starch market.
Major companies operating in the pharmaceuticals native starch market are focusing on developing innovative products, such as plant-based textures, to improve drug formulation and enhance patient compliance. Plant-based textures refer to physical properties derived from plant ingredients, such as thickness and gel strength, which help pharmaceuticals utilize native starch by improving tablet binding, disintegration, and mouthfeel, resulting in more natural and effective drug formulations. For example, in February 2024, Ingredion Incorporated, a US-based food company, introduced Novation Indulge 2940 starch, a clean-label texturizer designed to enhance texture and stability in both dairy and alternative dairy products. This innovative pharmaceutical native starch provides functional properties that support improved drug formulation performance, bioavailability, and controlled release while promoting the development of clean-label, sustainable products. Novation Indulge 2940 starch is a versatile ingredient that enhances texture, stability, and consumer acceptance using natural, clean-label components.
Major companies operating in the pharmaceuticals native starch market are Cargill Incorporated, Archer Daniels Midland Company, Ingredion Incorporated, Roquette Freres SA, Emsland Group, Tereos SCA, AGRANA Beteiligungs-AG, Grain Processing Corporation, Universal Starch-Chem Allied Ltd., SPAC Starch Products (India) Private Limited, Sanstar Biopolymers Ltd., Gulshan Polyols Ltd., Tate & Lyle Public Limited Company, BENEO GmbH, Hungrana Kft., Bluecraft Agro Pvt. Ltd., Visco Starch, Manildra Group, Shandong Liujia Pharmaceutical Excipient Co. Ltd., Zhucheng Xingmao Corn Developing Co. Ltd.
North America was the largest region in the pharmaceuticals native starch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceuticals native starch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the pharmaceuticals native starch market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The pharmaceuticals native starch market consists of sales of sorghum starch, barley starch, sweet potato starch, and arrowroot starch. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pharmaceuticals Native Starch Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses pharmaceuticals native starch market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pharmaceuticals native starch ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmaceuticals native starch market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.